Researchers at Fox Chase Cancer Center have developed a model that mimics patients’ tumor microenvironment that they believe has the potential to inform therapeutic decision making and presented a case study demonstrating the use of the model recently at the Atlantic Regional Hematopathology Meeting.
Read More
Fox Chase’s Cihangir Duy Receives an American Society of Hematology 2023 Scholar Award
February 17th 2023Cihangir Duy, PhD, MS, an assistant professor in the Nuclear Dynamics and Cancer research program and a member of the Cancer Epigenetics Institute at Fox Chase Cancer Center, has been awarded an American Society of Hematology 2023 Junior Faculty Scholar Award in basic/translational research.
Read More
Fox Chase Graduate Student Billy Truong Recognized With ASH Abstract Achievement Award
December 19th 2022Billy Truong, a doctoral candidate at Fox Chase Cancer Center, was awarded the American Society of Hematology Abstract Achievement Award for a poster that he presented at the 64th ASH Annual Meeting and Exposition.
Read More
Fox Chase Study Reveals Mechanism for Repairing DNA Damage Caused by Environmental Triggers
December 2nd 2022It’s long been known that DNA damage caused by environmental triggers, as well as other sources of oxidative stress, contribute to the development and progression of a wide variety of cancers.
Read More
Jaye Gardiner, PhD, a postdoctoral fellow at Fox Chase Cancer Center, was recently awarded the Merton Bernfield Memorial Award from the American Society for Cell Biology, making her one of 18 scientists from across the country to be recognized for their achievements in the life sciences.
Read More
In a recent study, researchers at Fox Chase Cancer Center demonstrated how cancer cells can survive in the body even when faced with a lack of sufficient nutrition, a finding that could be used as a potential indicator of disease status in the organs of pancreatic cancer patients.
Read More
Lapatinib May Boost Effectiveness of Drugs That Destroy Cancer Proteins by Blocking Resistance
September 2nd 2022Researchers at Fox Chase Cancer Center have discovered that the drug efflux pump MDR1 promotes resistance to a promising new class of drugs called PROTACS—proteolysis-targeting chimeras.
Read More